focus -WSS

focus

author：explore 2025-09-29 20:51:41 - browse：794

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Ancient Greek ideas underpin modern concepts of pregnancy

entertainment

WSS

All of Us, NIH's precision medicine initiative, gets a big boost

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

What is microchimerism and how does it affect maternal health?

All of Us, NIH's precision medicine initiative, gets a big boost

After Sarepta trial failure, Duchenne families brace for more debate

Live blog: Hearing on CRISPR

focus

focus

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Brain injuries and the importance of a second opinion

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Infant mortality in U.S. rose last year for first time in decades: CDC

What does generative AI mean for health care? We asked experts

Kidney transplant patients stopped immunosuppressants in trial

Anesthesiologist group: stop taking Ozempic before surgery

IVF doctors demand details after CooperSurgical lawsuit

United colonoscopy coverage change 'may cost lives,' doctors say

How to convince healthy people to buy insurance

Wikipedia

All of Us, NIH's precision medicine initiative, gets a big boost

Bill would allow buprenorphine prescription for addiction via telehealth

Medicare must police algorithms in Medicare Advantage, Dems say

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

The health care issue Democrats can’t solve: hospital reform

The health care issue Democrats can’t solve: hospital reform

knowledge

leisure time

entertainment

focus